Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reissued by analysts at Chardan Capital in a research report issued on Tuesday, AnalystRatings.com reports. They currently have a $72.50 price target on the stock. Chardan Capital’s price target indicates a potential upside of 90.99% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Barclays increased their price target on shares of Crispr Therapeutics from $59.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Jefferies Financial Group started coverage on shares of Crispr Therapeutics in a research note on Thursday, August 1st. They set a “buy” rating and a $64.00 price target on the stock. BTIG Research increased their price target on shares of Crispr Therapeutics from $51.00 to $59.00 and gave the company a “positive” rating in a research note on Tuesday, July 30th. Canaccord Genuity started coverage on shares of Crispr Therapeutics in a research note on Friday, July 26th. They set a “buy” rating and a $72.00 price target on the stock. Finally, Roth Capital increased their price target on shares of Crispr Therapeutics from $50.00 to $65.00 in a research note on Tuesday, July 30th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $57.25.
Crispr Therapeutics stock traded up $1.28 during trading hours on Tuesday, hitting $37.96. 358,628 shares of the stock were exchanged, compared to its average volume of 609,785. The company has a debt-to-equity ratio of 0.10, a quick ratio of 13.96 and a current ratio of 13.96. The stock has a market capitalization of $2.02 billion, a P/E ratio of -11.03 and a beta of 3.11. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $53.90. The business’s 50-day moving average is $43.76 and its two-hundred day moving average is $43.30.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Benjamin Edwards Inc. lifted its holdings in Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares during the period. US Bancorp DE lifted its holdings in Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after buying an additional 526 shares during the period. BSW Wealth Partners acquired a new position in Crispr Therapeutics in the second quarter valued at approximately $39,000. BNP Paribas Arbitrage SA acquired a new position in Crispr Therapeutics in the second quarter valued at approximately $41,000. Finally, Griffin Asset Management Inc. acquired a new position in Crispr Therapeutics in the second quarter valued at approximately $64,000. 50.23% of the stock is currently owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: How to track put option volume
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.